Profile of temsirolimus in the treatment of advanced renal cell carcinoma

Temsirolimus is a potent inhibtor of the mammalian target of rapamycin (mTOR). In various clinical trials temsirolimus has shown an overall survival benefit for patients with metastatic renal cell carcinoma (mRCC). Thus it is approved for first-line therapy in high-risk mRCC patients. We discuss the...

Descripción completa

Detalles Bibliográficos
Autores principales: Staehler, Michael, Haseke, Nicolas, Khoder, Wael, Stief, Christian G
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962305/
https://www.ncbi.nlm.nih.gov/pubmed/21049085
_version_ 1782189188145217536
author Staehler, Michael
Haseke, Nicolas
Khoder, Wael
Stief, Christian G
author_facet Staehler, Michael
Haseke, Nicolas
Khoder, Wael
Stief, Christian G
author_sort Staehler, Michael
collection PubMed
description Temsirolimus is a potent inhibtor of the mammalian target of rapamycin (mTOR). In various clinical trials temsirolimus has shown an overall survival benefit for patients with metastatic renal cell carcinoma (mRCC). Thus it is approved for first-line therapy in high-risk mRCC patients. We discuss the indication, side effects and clinical implications of temsirolimus treatment.
format Text
id pubmed-2962305
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-29623052010-11-03 Profile of temsirolimus in the treatment of advanced renal cell carcinoma Staehler, Michael Haseke, Nicolas Khoder, Wael Stief, Christian G Onco Targets Ther Review Temsirolimus is a potent inhibtor of the mammalian target of rapamycin (mTOR). In various clinical trials temsirolimus has shown an overall survival benefit for patients with metastatic renal cell carcinoma (mRCC). Thus it is approved for first-line therapy in high-risk mRCC patients. We discuss the indication, side effects and clinical implications of temsirolimus treatment. Dove Medical Press 2010-10-05 /pmc/articles/PMC2962305/ /pubmed/21049085 Text en © 2010 Staehler et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Staehler, Michael
Haseke, Nicolas
Khoder, Wael
Stief, Christian G
Profile of temsirolimus in the treatment of advanced renal cell carcinoma
title Profile of temsirolimus in the treatment of advanced renal cell carcinoma
title_full Profile of temsirolimus in the treatment of advanced renal cell carcinoma
title_fullStr Profile of temsirolimus in the treatment of advanced renal cell carcinoma
title_full_unstemmed Profile of temsirolimus in the treatment of advanced renal cell carcinoma
title_short Profile of temsirolimus in the treatment of advanced renal cell carcinoma
title_sort profile of temsirolimus in the treatment of advanced renal cell carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962305/
https://www.ncbi.nlm.nih.gov/pubmed/21049085
work_keys_str_mv AT staehlermichael profileoftemsirolimusinthetreatmentofadvancedrenalcellcarcinoma
AT hasekenicolas profileoftemsirolimusinthetreatmentofadvancedrenalcellcarcinoma
AT khoderwael profileoftemsirolimusinthetreatmentofadvancedrenalcellcarcinoma
AT stiefchristiang profileoftemsirolimusinthetreatmentofadvancedrenalcellcarcinoma

Ejemplares similares